LBA7Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag). (25th November 2018) - Hochmair, M J; Morabito, A; Hao, D; Yang, C-T; Soo, R A; Yang, J C-H; Gucalp, R; Halmos, B; Wang, L; Golembesky, A; Märten, A; Cufer, T